Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Gilead Sciences
Historiska aktiekurser
Aktuell aktiekurs	US$125.05
52 veckors högsta	US$157.29
52 veckors lägsta	US$104.46
Beta	0.33
1 månads förändring	-6.93%
3 månaders förändring	-9.55%
1 års förändring	16.65%
3 års förändring	64.52%
5 års förändring	84.09%
Förändring sedan börsintroduktionen	19,661.00%

Senaste nyheter och uppdateringar

Seeking Alpha • Jun 23

Gilead Sciences: The Market Is Underestimating Its Growth Runway

Summary Gilead Sciences offers a compelling long-term value opportunity after a significant pullback, with a "Buy" rating reaffirmed. GILD's core HIV franchise drives 72% of sales, with robust growth from Biktarvy and rapid adoption of Yeztugo, now expected to reach $1 billion in annual sales. Management raised 2026 revenue growth guidance to 5.5% at midpoint, citing strong HIV performance and momentum in oncology with Trodelvy. GILD maintains a strong A- rated balance sheet, low leverage, and a well-covered 2.65% dividend, supporting future strategic flexibility. Read the full article on Seeking Alpha

Uppdatering av berättelse • Jun 12

GILD: Diversified Oncology And HIV Pipeline Will Support Future Earnings

Analyst price targets for Gilead Sciences have been refined to $180.00, with updated assumptions reflecting slightly lower revenue growth, a modestly higher profit margin, a small reduction in the discount rate, and a marginally lower future P/E, as analysts balance enthusiasm for assets like Trodelvy, Yeztugo, lenacapavir, and the Tubulis platform against more cautious long term expectations. Analyst Commentary Recent Street research shows a mix of enthusiasm and caution around Gilead, with bullish analysts highlighting specific growth drivers and valuation support while others keep a more measured stance on key oncology and I&I assets.

Recent updates

Seeking Alpha • Jun 23

Gilead Sciences: The Market Is Underestimating Its Growth Runway

Uppdatering av berättelse • Jun 12

GILD: Diversified Oncology And HIV Pipeline Will Support Future Earnings

Uppdatering av berättelse • May 28

GILD: HIV And Oncology Pipeline Expansion Will Drive Long Term Upside

Gilead Sciences' updated analyst price target edges up to $157.83 from $157.43, with analysts pointing to slightly higher modeled revenue growth, a modestly higher assumed future P/E of about 22.4x, and the growing contribution they see from assets like Trodelvy, Yeztugo and the Tubulis platform, even as views on long term oncology and I&I potential remain restrained. Analyst Commentary Analysts are split between those leaning into Gilead's newer growth drivers and those keeping a closer eye on execution risks and valuation.

Ny berättelse • May 19

Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase

Below is a professional investment memo (buy‑side style, in English) on Gilead Sciences (GILD) based primarily on the 2025 Impact Report (pipeline + strategy + data extraction) and complemented with verified investor website + latest news analysis. Investment Memo – Gilead Sciences (NASDAQ: GILD) 1.

Uppdatering av berättelse • May 01

GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions

Analysts have raised the Gilead Sciences fair value estimate by about $2 to $128.42 per share, supported by refreshed models that reflect updated revenue growth, profitability, and future P/E assumptions following a wave of higher Street price targets. Analyst Commentary Street research on Gilead has tilted constructive in recent weeks, with several firms lifting price targets and at least one new Buy rating added.

Uppdatering av berättelse • Apr 17

GILD: Oncology Deals And HIV Franchise Will Support Future Earnings

Analysts have raised the price target for Gilead Sciences to $180, citing recent upward revisions across Wall Street that reflect updated views on revenue growth, profitability and oncology deal activity. The core fair value estimate in this framework also remains at $180.

Uppdatering av berättelse • Apr 03

GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength

Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.

Uppdatering av berättelse • Mar 20

GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook

The analyst fair value estimate for Gilead Sciences has moved from $132.57 to $157.43, with analysts pointing to stronger modeled revenue growth, slightly higher long term profit margins, and a higher future P/E multiple supported by recent price target hikes and positive views on the company's positioning in large cap biotech. Analyst Commentary Recent Street research on Gilead Sciences reflects a mix of optimism around growth drivers and caution around valuation and competitive risks.

Uppdatering av berättelse • Mar 05

GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions

Analysts have lifted their Gilead Sciences fair value estimate from $122.64 to $126.09 as they update models to reflect revised revenue growth and profit margin assumptions, along with a slightly higher discount rate and a modestly lower future P/E multiple, following a wave of higher Street price targets in recent weeks. Analyst Commentary Recent Street research around Gilead Sciences shows a mix of optimism and restraint.

Uppdatering av berättelse • Feb 19

GILD: Elevated Future Expectations Will Hinge On Execution In Oncology

Gilead Sciences' updated analyst price target has moved sharply higher to $122.64 from $91.83, as analysts broadly lift their targets into the $140 to $170 range, citing steadier HIV franchise expectations, contributions from recent launches, and adjusted assumptions for expenses and oncology assets. Analyst Commentary Recent Street research shows a clear tilt toward higher valuation frameworks for Gilead Sciences, with several firms taking their targets into a broad US$140 to US$170 range.

Uppdatering av berättelse • Feb 05

GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power

Narrative Update: Gilead Sciences Analyst Price Target Shift Analysts have lifted their price targets on Gilead Sciences by as much as US$20, pointing to updated HIV franchise expectations, revised oncology and PrEP assumptions, and refreshed valuation approaches, even as some models incorporate higher IPR&D expenses and adjusted sales forecasts. Analyst Commentary Recent Street research around Gilead centers on two big themes in the models: the durability of the HIV franchise and the ramp in newer areas like PrEP and oncology, with several bullish analysts lifting price targets and reaffirming positive ratings.

Uppdatering av berättelse • Jan 22

GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power

Analysts have nudged their fair value estimate for Gilead Sciences up to $159 from $153, citing refreshed models that reflect updated HIV franchise expectations, oncology pipeline inputs, and evolving competitive readthroughs from peers in hepatitis and cell therapy. Analyst Commentary Recent Street research around Gilead Sciences has leaned constructive, with several bullish analysts refining their models and resetting price targets while pointing to HIV, oncology, and select liver and autoimmune assets as the key drivers they are watching.

Uppdatering av berättelse • Jan 07

GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook

Analysts have nudged their price targets on Gilead Sciences higher, generally toward the US$140 to US$145 range. They cite expectations for stronger HIV PrEP contributions from Yeztugo, a healthier outlook for the broader HIV portfolio including Biktarvy, and ongoing support from oncology and newer launches such as Livdelzi.

Uppdatering av berättelse • Dec 20

GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power

Analysts have raised their fair value estimate for Gilead Sciences to $153 from $140, citing extended Biktarvy exclusivity, a stronger long term HIV growth outlook supported by Yeztugo and PrEP, and increasing conviction in oncology and broader large cap biopharma innovation potential. Analyst Commentary Bullish analysts continue to highlight Gilead as a core large cap biopharma holding, pointing to a healthier long term growth profile in HIV and a strengthening contribution from oncology.

Uppdatering av berättelse • Dec 06

GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead

Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.

Uppdatering av berättelse • Nov 22

GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures

Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.

Uppdatering av berättelse • Nov 08

GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead

Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.

Uppdatering av berättelse • Oct 25

Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies

Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.

Uppdatering av berättelse • Oct 10

Global Healthcare Trends Will Expand Access To Advanced Therapies

Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.

Uppdatering av berättelse • Sep 04

Global Healthcare Trends Will Expand Access To Advanced Therapies

Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.

Analysartikel • Jul 27

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Aktieägarnas avkastning

	GILD	US Biotechs	US Marknad
7D	-1.7%	4.0%	-2.3%
1Y	16.7%	34.1%	21.2%

Avkastning vs industri: GILD presterade sämre än US Biotechs branschen som gav 34.1 % under det senaste året.

Avkastning vs Marknaden: GILD presterade sämre än US marknaden som gav 21.2 % under det senaste året.

Prisvolatilitet

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement	3.3%
Biotechs Industry Average Movement	10.6%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.1%

Stabil aktiekurs: GILD har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: GILD s veckovolatilitet ( 3% ) har varit stabil under det senaste året.

Om företaget

Grundad	Anställda	VD OCH KONCERNCHEF	Webbplats
1987	17,000	Dan O'Day	www.gilead.com

Gilead Sciences, Inc. är ett biofarmaceutiskt företag som upptäcker, utvecklar och marknadsför läkemedel inom områden där det finns ett stort medicinskt behov i USA, Europa och internationellt. Företaget tillhandahåller Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza och Yeztugo för behandling av hiv-1-infektion hos patienter. Det tillhandahåller också Epclusa, Livdelzi och Vemlidy för behandling av kroniskt hepatit C-virus, primär biliär kolangit och kroniskt hepatit B-virus; Tecartus, en T-cellsterapi för behandling av vuxna patienter; Trodelvy, en injektion för intravenös användning; och Yescarta, en suspension för intravenös infusion, är en CAR T-cellsterapi för behandling av vuxna patienter.

Gilead Sciences, Inc. Sammanfattning av grunderna

Hur förhåller sig Gilead Sciences:s resultat och omsättning till dess börsvärde?
GILD grundläggande statistik
Börsvärde	US$155.03b
Vinst(TTM)	US$9.22b
Intäkter(TTM)	US$29.74b

16.8x

P/E-förhållande

5.2x

P/S-förhållande

Är GILD övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
GILD resultaträkning (TTM)
Intäkter	US$29.74b
Kostnad för intäkter	US$6.14b
Bruttovinst	US$23.60b
Övriga kostnader	US$14.39b
Intäkter	US$9.22b

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)	7.42
Bruttomarginal	79.37%
Nettovinstmarginal	30.99%
Skuld/egenkapitalförhållande	94.6%

Hur har GILD utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Utdelningar

2.6%

Aktuell utdelningsavkastning

43%

Utbetalningskvot

Ger GILD en tillförlitlig utdelning?

Se GILD utdelningshistorik och jämförelsetal

När behöver man köpa GILD för att få en kommande utdelning?
Gilead Sciences datum för utdelning
Ex utdelningsdag	Jun 15 2026
Utbetalningsdag för utdelning	Jun 29 2026
Dagar till Ex-utdelning	10 days
Dagar till utdelningsdag	4 days

Ger GILD en tillförlitlig utdelning?

Se GILD utdelningshistorik och jämförelsetal

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/06/23 14:45
Aktiekurs vid dagens slut	2026/06/23 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Gilead Sciences, Inc. bevakas av 65 analytiker. 24 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
David Toung	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Gilead Sciences (GILD) Aktievy

Belöningar

Riskanalys

Analyst Price Targets

Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies

Lenacapavir And Trodelvy Launches Will Serve A Growing Aging Market

Biktarvy And Lenacapavir Launches Will Drive Cautious Future Progress

Top Community Narratives

Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase

Top Community Narratives

Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase

Top Analyst Narratives

Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies

Lenacapavir And Trodelvy Launches Will Serve A Growing Aging Market

Biktarvy And Lenacapavir Launches Will Drive Cautious Future Progress

Gilead Sciences, Inc. Konkurrenter

Amgen

Vertex Pharmaceuticals

AbbVie

Regeneron Pharmaceuticals

Prishistorik och prestanda

Senaste nyheter och uppdateringar

Gilead Sciences Announces European Commission Approval for Trodelvy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer

Gilead Sciences: The Market Is Underestimating Its Growth Runway

FDA Accepts Gilead Application for Once-Weekly Oral HIV Prevention Tablet Yeztugo

Gilead Sciences Receives Fda Acceptance for Supplemental New Drug Application for Once-Weekly Oral Yeztugo for Hiv Prevention

Gilead Advances HIV and Liver Therapies as Cancer Trial Ends and Ebola Aid Expands

GILD: Diversified Oncology And HIV Pipeline Will Support Future Earnings

Recent updates

Gilead Sciences Announces European Commission Approval for Trodelvy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer

Gilead Sciences: The Market Is Underestimating Its Growth Runway

FDA Accepts Gilead Application for Once-Weekly Oral HIV Prevention Tablet Yeztugo

Gilead Sciences Receives Fda Acceptance for Supplemental New Drug Application for Once-Weekly Oral Yeztugo for Hiv Prevention

Gilead Advances HIV and Liver Therapies as Cancer Trial Ends and Ebola Aid Expands

GILD: Diversified Oncology And HIV Pipeline Will Support Future Earnings

Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment

Upcoming dividend of US$0.82 per share

Gilead Sciences Advances Cancer and Liver Disease Treatments With New Phase 3 Data and EMA Support

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others.

Gilead Sciences Announces Statistically Significant Composite ALP Normalization With Livdelzi In Phase 3 IDEAL Trial In Primary Biliary Cholangitis

Gilead Sciences Shares Interim Phase 3 ASSURE Data Demonstrating High And Sustained ALP Normalization With Livdelzi (Seladelpar) In People With Primary Biliary Cholangitis

GILD: HIV And Oncology Pipeline Expansion Will Drive Long Term Upside

Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase

Insider notifies of intention to sell stock

First quarter dividend of US$0.82 announced

First quarter 2026 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall from profit to US$2.74 loss

Gilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus Lenacapavir

GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.

Gilead Sciences, Inc. to Report Q1, 2026 Results on May 07, 2026

Insider notifies of intention to sell stock

GILD: Oncology Deals And HIV Franchise Will Support Future Earnings

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.

GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others for $2.2 billion.

Gilead Sciences, Inc., Annual General Meeting, Apr 30, 2026

Chief Financial Officer notifies of intention to sell stock

GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook

Chairman & CEO exercised options and sold US$1.5m worth of stock

Upcoming dividend of US$0.82 per share

GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions

Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026

GILD: Elevated Future Expectations Will Hinge On Execution In Oncology

Insider notifies of intention to sell stock

Gilead Sciences, Inc. to Present New Hiv Treatment and Prevention Data At Croi 2026, with A Focus on Expanding Options

Fourth quarter dividend increased to US$0.82

New minor risk - Financial position

Full year 2025 earnings: Revenues and EPS in line with analyst expectations

Price target increased by 13% to US$152

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2026

Chairman & CEO exercised options and sold US$9.7m worth of stock

Fda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System Lymphoma

GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power

Gilead Sciences, Inc. to Report Q4, 2025 Results on Feb 10, 2026

Chairman & CEO exercised options and sold US$8.0m worth of stock

GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power

Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast Cancer

GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook

GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power